Construction method of novel host bacteria for highly expressing human serum albumin

By designing and optimizing genes and constructing recombinant expression vectors, combining electroconversion and optimized fermentation processes, the problems of low gene expression levels and immature purification processes are solved, and efficient human serum albumin expression and high purity preparation are achieved.

CN119020392APending Publication Date: 2024-11-26HEBEI HUAKAI HUIHE BIOMEDICAL CO LTD
View PDF 0 Cites 2 Cited by

Patent Information

Application Number
CN202411108150.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-13
Publication Date
2024-11-26

AI Technical Summary

Technical Problem

The existing preparation of genetic recombinant human serum albumin has problems such as low gene expression level, immature control of the fermentation process, and immature purification process of recombinant human serum albumin, resulting in a variety of purification steps, low purification efficiency and recovery rate.

Method used

Design an optimized gene encoding human serum albumin, and transform Pichia Pasteur host bacteria by electroconversion by constructing a recombinant expression vector. Use G418 resistance gene to screen high copy number transformants, optimize the fermentation and purification process to improve expression and purity.

Benefits of technology

A new host bacteria that expresses human serum albumin at a high level was achieved, with a purity of more than 99%, simplifying the purification steps and improving the purification efficiency and recovery rate.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119020392A_ABST
    Figure CN119020392A_ABST
Patent Text Reader

Abstract

The invention discloses a construction method of a novel host bacterium for highly expressing human serum albumin, and belongs to the biotechnical field of preparation of human serum albumin. Comprising the following steps: S100, designing an optimized gene for coding human serum albumin; s200, constructing a recombinant expression vector; and S300, transforming the recombinant expression vector obtained in the step S200 into a pichia pastoris host bacterium by using an electrotransformation method to obtain the novel host bacterium. Through molecular level target gene complete sequence optimization design, a target gene which is most suitable for expression of pichia pastoris is obtained; at the cellular level, international latest host bacteria CBS7435 of a pichia pastoris expression system are introduced for gene expression of the human serum albumin; the G418 resistance gene is used for screening pichia pastoris transformants containing exogenous genes with high copy number, is used for constructing novel engineering bacteria with high-level expression of recombinant human serum albumin and can be used for preparing the human serum albumin, and the purity of the human serum albumin reaches 99% or above.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the biotechnology field of preparing human serum albumin by utilizing genetic engineering technology, and specifically is a method for constructing a novel host bacterium that highly expresses human serum albumin. Background Art

[0002] Advances in molecular biology techniques have provided numerous methods and approaches for producing exogenous proteins using bioreactors. To date, a variety of exogenous protein expression systems have been developed, including those in Escherichia coli, yeast, insects, and mammalian cells. After nearly three decades of development, the Pichia pastoris gene expression system, exemplified by the host strain GS115 (Cregg et al. (2009). Methods Enzymol. 463, 169–189; US Patent 4,879,231, Phillips Petroleum, 1989), has become one of the most important hosts for expressing exogenous proteins. This system features ease of high-density fermentation, stable integration of the target gene into the host genome, efficient secretion and appropriate glycosylation of the expressed product, and economical culture medium. This gene expression system utilizes the highly efficient and regulatable promoter AOX1 and has efficiently expressed thousands of exogenous proteins such as HBsAg, TNF, EGF, tetanus toxin C fragment, genetically engineered antibodies, etc., proving that this system is efficient, practical, simple, and has the outstanding characteristics of increasing expression levels while maintaining the biological activity of the products. It is also very suitable for pilot-scale expansion and expansion to industrial-scale production.

[0003] Expressing a foreign gene in Pichia pastoris generally involves the following steps: ① Inserting the foreign gene into a recombinant expression vector; ② Treating the linearized recombinant plasmid with endonucleases and transforming the Pichia pastoris strain; ③ Plating the transformant on MD plates for the first round of screening for positive recombinants; ④ Screening for positive recombinants in the second round using YPD plates containing varying concentrations of G418; ⑤ Further characterizing the integration of the foreign gene into the yeast genome; ⑥ Inducing expression on a small scale to determine the expression level of the foreign gene; ⑦ Large-scale fermentation in a bioreactor and preparing the recombinant protein from the fermentation broth. To increase the expression of a foreign gene in Pichia pastoris, it is often necessary to screen for Pichia pastoris transformants containing a high copy number of the foreign gene, essentially increasing the gene dosage within the host strain. Screening for high-copy number transformants is accomplished by gradually increasing G418 resistance, a complex and often random process. Furthermore, the correlation between high-copy number Pichia transformants and high expression of the foreign protein remains variable, as different target genes exhibit different optimal copy numbers, and a non-linear relationship does not exist between the two. The G418 resistance gene has been introduced into a series of commonly used recombinant expression vectors in Pichia pastoris, such as pIC9K and pIC3.5K. After transformation into the host bacteria, both the foreign gene and the resistance gene are integrated into the Pichia chromosome via homologous recombination. By enhancing G418 resistance screening, transformants containing the target gene, which may harbor multiple copies of the target gene, can be identified within the transformant population.

[0004] To screen for high-copy-number positive clones, G418 plates with varying concentration gradients are used for screening. Preliminary experiments used a G418 concentration gradient of 0, 0.25, 0.5, 0.75, 1.0, 1.5, 1.75, 2.0, 3.0, and 4.0 mg / ml. The screening protocol recommended by Invitrogen describes the following screening strategies. The first method involves preparing G418 plates with varying concentration gradients and then using a photocopying method to copy-copy positive clones from HIS4-deficient plates onto the G418 gradient plates for screening of high-copy-number clones. This method is characterized by a significant workload (three consecutive transfer cultures are required before copying to ensure that each transformant has a consistent concentration during copying), a high screening difficulty, a long cycle time, and a relatively small number of transformants screened, making it impractical for high-throughput screening. The second method also requires the preparation of G418 plates with different concentration gradients. The difference is that all positive transformants grown on the HIS4 auxotrophic plates can be washed with sterile water or liquid culture medium, then diluted to a suitable concentration, and a certain amount of dilution liquid is applied to the plates containing G418 with different concentration gradients. This method is relatively simple to operate and can screen more transformants. However, for those containing different target genes or different Pichia pastoris host bacteria, preliminary experiments need to be performed in advance to explore the dilution of the bacterial solution. These two screening schemes are the universal screening methods currently used by scientific and technological workers at home and abroad when expressing foreign proteins using the Pichia pastoris expression system. However, their common disadvantages are that the amount of G418 used is large, the operation is complicated, the workload is large, and it is time-consuming and labor-intensive. The versatility of the screening methods for different Pichia pastoris host bacteria is poor. Summary of the Invention

[0005] 1. Technical problem to be solved by the invention

[0006] The present invention aims to address the problems of existing recombinant human serum albumin preparation products, such as low gene expression levels, immature fermentation process control technology (due to the large scale of fermentation, large fermentation tanks of ten or several dozen tons are often required, and there is a lack of precedent and tools for process control and detection of large tanks), and immature recombinant human serum albumin purification technology (due to recombinant human serum albumin being a special case, the purification scale and equipment of the target protein are particularly large-scale, and the purity requirement of the target protein is particularly high, reaching a purity of 99.99% or above), namely, as many as a dozen purification steps, low purification medium loading capacity, low purification efficiency and low purification recovery rate.

[0007] 2. Technical solution

[0008] In order to achieve the above object, the technical solution provided by the present invention is:

[0009] A method for constructing a novel host bacterium that highly expresses human serum albumin according to the present invention comprises the following steps:

[0010] S100, design an optimized gene encoding human serum albumin;

[0011] S200, constructing a recombinant expression vector;

[0012] S300, transforming the recombinant expression vector obtained in step S200 into a Pichia pastoris host bacterium by electroporation to obtain the novel host bacterium.

[0013] Preferably, the optimized gene encoding human serum albumin in step S100 comprises a nucleotide sequence as shown in SEQ ID NO: 2, and an amino acid sequence as shown in SEQ ID NO: 3.

[0014] Preferably, in the optimized gene encoding human serum albumin in step S100, the preferred codons of the Pichia pastoris alcohol oxidase (AOX1) gene are selected and the preferred codons of the gene are controlled to account for 90% of the total number of codons encoded in the optimized gene.

[0015] Preferably, in the optimized gene encoding human serum albumin in step S100, three restriction endonuclease sites, namely SalI, HindIII and XbaI, are sequentially inserted from 5' to 3' direction inside the optimized gene, so that the optimized gene is relatively evenly divided into four large fragments.

[0016] Preferably, in the optimized gene encoding human serum albumin in step S100, continuous GC pairings are reduced and AT pairings preferred by Pichia pastoris are increased, so that the GC content within the optimized gene is adjusted to 45-50%.

[0017] Preferably, the optimized gene encoding human serum albumin in step S100 also includes an expression reading frame of

[0018] The 5' restriction endonuclease BamHI site was inserted into the 5' regulatory region (promoter region) of the AOX1 gene, followed by 10 deoxyoligonucleotides CCAAACGATG (containing the Kozak sequence of eukaryotic genes, i.e., AXXATG), and then the yeast α-mating child leader peptide (85 amino acids) sequence from Saccharomyces cerevisiae. The HSA mature gene was then inserted between EcoRI and NotI in the multiple cloning site of the pPIC9K recombinant expression vector;

[0019] The coding sequence AAAAGA for two dibasic amino acids (-Lys-Arg-) of lysine and arginine was inserted after the EcoRI restriction site at the 5' end of the target gene. The specific sequence is SEQ ID NO: 4. The double termination codon TAATAG was inserted before the NotI restriction site at the 3' end of the target gene. The specific sequence is SEQ ID NO: 5.

[0020] Preferably, the recombinant expression vector constructed in step S200 is specifically

[0021] The optimized gene encoding human serum albumin synthesized by chemical synthesis was cut from the cloning vector using EcoRI-NotI double enzyme digestion, and the target gene fragment was recovered using a DNA recovery kit from the cut gel strip of corresponding size; the fragment containing the target gene was cloned into the recombinant expression vector digested with the corresponding double enzyme digestion to construct the recombinant expression vector.

[0022] Preferably, the step S300 specifically comprises linearizing the recombinant expression vector obtained in step S200 using restriction endonuclease SacI or Bgl II, and transforming the linearized recombinant expression vector into a Pichia pastoris host bacterium using an electroporation method to obtain the novel host bacterium.

[0023] Preferably, the nucleotide sequence of the recombinant expression vector is shown in SEQ ID NO: 1.

[0024] Preferably, the recombinant expression vector is any one of pPIC9, pPIC3, pPICZαABC, pPIC3.5K, pHIL-S1, pHIL-D2, pA0804, pA0815, pGAPZαABC, pPIC6αABC, and pPIC9K.

[0025] Preferably, the recombinant expression vector is HSA-pPIC9K.

[0026] Preferably, the Pichia pastoris host strain is Pichia pastoris CBS7435.

[0027] Preferably, the novel host bacteria is Pichia pastoris HSA-C16, which is deposited in the General Microbiology Center of China Culture Collection Administration, with a deposit number of CGMCC No. 30175 and a deposit date of March 28, 2024.

[0028] 3. Beneficial effects

[0029] Compared with the prior art, the technical solution provided by the present invention has the following beneficial effects:

[0030] The present invention provides a method for constructing a novel host strain for high expression of human serum albumin, comprising the steps of S100, designing an optimized gene encoding human serum albumin; S200, constructing a recombinant expression vector; and S300, transforming the recombinant expression vector obtained in step S200 into a Pichia pastoris host strain using electroporation to obtain the novel host strain. The method optimizes the full sequence of the target gene at the molecular level to obtain the target gene optimally expressed in Pichia pastoris. At the cellular level, the method introduces the internationally latest Pichia pastoris expression system host strain CBS7435 for human serum albumin gene expression. Furthermore, the G418 resistance gene is used to screen Pichia pastoris transformants containing a high copy number of the exogenous gene, thereby constructing a novel engineered strain for high-level expression of recombinant human serum albumin, which can be used to produce human serum albumin with a purity exceeding 99%.

[0031] Biological deposit description Pichia pastoris HSA-C16 was deposited in the General Microbiology Center of China Culture Collection Administration (CGMCC) on March 28, 2024. The deposit address is Institute of Microbiology, Chinese Academy of Sciences, No. 3, Yard 1, Beichen West Road, Chaoyang District, Beijing, and the deposit number is CGMCC No. 30175. BRIEF DESCRIPTION OF THE DRAWINGS

[0032] Figure 1 This is a schematic diagram of a computer-simulated alignment curve in which the GC pairing content within the nucleotide sequence of the optimized gene as shown in SEQ ID NO: 2 of the embodiment is adjusted to an optimal ratio;

[0033] Figure 2 This is a map of the Pichia pastoris multi-copy recombinant expression vector pPIC9K of the embodiment;

[0034] Figure 3 Agarose gel electrophoresis (1% agarose gel) of the optimized genes of the embodiment;

[0035] Figure 4 Schematic diagram of the construction process of the recombinant plasmid of the embodiment;

[0036] Figure 5 Optimized gene nucleotide sequence analysis map 1 of the embodiment;

[0037] Figure 6 The second analysis map of the optimized gene nucleotide sequence of the embodiment;

[0038] Figure 7 Optimized gene nucleotide sequence analysis map 3 of the embodiment;

[0039] Figure 8 This is a schematic diagram of the cell state changes when the recombinant plasmid is transformed into the Pichia pastoris host bacteria by electroporation in the embodiment;

[0040] Figure 9 Schematic diagram of the cell state changes when the recombinant plasmid is transformed into the Pichia pastoris GS115 host bacteria by electroporation in the embodiment;

[0041] Figure 10 Schematic diagram of the cell state changes when the recombinant plasmid is transformed into the host bacteria Pichia pastoris CBS7435 by electroporation in the embodiment;

[0042] Figure 11 Results of a small-scale induction experiment of the Pichia pastoris GS115 engineered strain prepared in this example Figure 1 ;

[0043] Figure 12 Results of a small-scale induction experiment of the Pichia pastoris GS115 engineered strain prepared in this example Figure 2 ;

[0044] Figure 13 The results of the pilot induction experiment of the Pichia pastoris CBS7435 engineered strain prepared in the example Figure 1 ;

[0045] Figure 14 The results of the pilot induction experiment of the Pichia pastoris CBS7435 engineered strain prepared in the example Figure 2 ;

[0046] Figure 15 Schematic diagram of protein electrophoresis at different time points of the fermentation test of the engineered strain prepared in the example in a 50L fermenter Figure 1 ;

[0047] Figure 16 Schematic diagram of protein electrophoresis at different time points of the fermentation test of the engineered strain prepared in the example in a 50L fermenter Figure 2 ;

[0048] Figure 17 Schematic diagram of protein electrophoresis at different time points of the fermentation test of the engineered strain prepared in the example in a 50L fermenter Figure 3 ;

[0049] Figure 18 The standard curve for quantitative determination of protein concentration using bovine serum albumin as a standard in the embodiment;

[0050] Figure 19 Schematic diagram of the separation and purification results of the supernatant sample of the engineered strain prepared in the example in a 50L fermenter Figure 1 ;

[0051] Figure 20 This is a purity identification data diagram of the serum albumin sample obtained by purification in Example;

[0052] Figure 21 Schematic diagram of the non-reduced molecular weight TIC analysis comparison of the serum albumin sample purified in Example and the rHSA national standard;

[0053] Figure 22 Schematic diagram of the comparison of the reduced molecular weight TIC spectrum analysis of the serum albumin sample purified in Example and the rHSA national standard;

[0054] Figure 23 Schematic diagram of the comparison of reduced molecular weight mass spectrometry analysis of the serum albumin sample purified in Example and the rHSA national standard. DETAILED DESCRIPTION

[0055] In order to enable those skilled in the art to better understand the present invention, the following will clearly and completely describe the technical solutions in the embodiments of the present invention in conjunction with the drawings in the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments in the present invention, all other embodiments obtained by ordinary technicians in this field without making creative efforts should fall within the scope of protection of this application.

[0056] It should be noted that the terms "first", "second", etc. in the specification and claims of the present application and the above-mentioned drawings are used to distinguish similar objects and are not necessarily used to describe a specific order or sequential order. It should be understood that the data used in this way can be interchanged where appropriate, so that the embodiments of the present application described here. In addition, the terms "including" and "having" and any of their variations are intended to cover non-exclusive inclusions. For example, a process, method, system, product or device that includes a series of steps or units is not necessarily limited to those steps or units clearly listed, but may include other steps or units that are not clearly listed or inherent to these processes, methods, products or devices.

[0057] In this application, terms such as "upper," "lower," "left," "right," "front," "back," "top," "bottom," "inner," "outer," "center," "vertical," "horizontal," "transverse," and "longitudinal" indicate positions or locations based on the positions or locations shown in the accompanying drawings. These terms are primarily intended to better describe this application and its embodiments and are not intended to limit the devices, elements, or components indicated to having a specific orientation, or to being constructed or operated in a specific orientation.

[0058] Furthermore, some of the above terms may be used to express other meanings besides indicating a position or location. For example, the term "on" may also be used to indicate a dependency or connection in certain circumstances. Those skilled in the art will understand the specific meanings of these terms in this application based on the specific circumstances.

[0059] Furthermore, the terms "installed," "disposed," "provided with," "connected," "connected," and "socketed" should be interpreted broadly. For example, they can refer to fixed connections, removable connections, or integral structures; mechanical connections or electrical connections; direct connections, indirect connections through an intermediary, or internal communication between two devices, elements, or components. Those skilled in the art will understand the specific meanings of these terms in this application based on the specific circumstances.

[0060] It should be noted that, in the absence of conflict, the embodiments and features of the embodiments in this application can be combined with each other. The present application will be described in detail below with reference to the accompanying drawings and in combination with the embodiments.

[0061] Example 1

[0062] This embodiment provides a method for constructing a novel host bacterium that highly expresses human serum albumin. The construction method includes:

[0063] S100, design an optimized gene encoding human serum albumin;

[0064] S200, constructing a recombinant expression vector;

[0065] S300, transforming the recombinant expression vector obtained in step S200 into a Pichia pastoris host bacterium by electroporation to obtain the novel host bacterium.

[0066] The optimized gene encoding human serum albumin in step S100 contains a nucleotide sequence as shown in SEQ ID NO: 2, and an amino acid sequence as shown in SEQ ID NO: 3.

[0067] In the step S100 , the preferred codons of the Pichia pastoris alcohol oxidase (AOX1) gene are selected from the optimized gene encoding human serum albumin, and the preferred codons of the gene are controlled to account for 90% of the total number of codons encoded in the optimized gene.

[0068] In the optimized gene encoding human serum albumin in step S100, three restriction endonuclease sites, namely SalI, HindIII and XbaI, are sequentially inserted from 5' to 3' inside the optimized gene, so that the optimized gene is relatively evenly divided into four large fragments.

[0069] In the step S100 , in the optimized gene encoding human serum albumin, continuous GC pairings are reduced and AT pairings preferred by Pichia pastoris are increased, so that the GC content within the optimized gene is adjusted to 45-50%.

[0070] Preferably, the optimized gene encoding human serum albumin in step S100 also includes an expression reading frame of

[0071] The 5' restriction endonuclease BamHI site was inserted into the 5' regulatory region (promoter region) of the AOX1 gene, followed by 10 deoxyoligonucleotides CCAAACGATG (containing the Kozak sequence of eukaryotic genes, i.e., AXXATG), and then the yeast α-mating child leader peptide (85 amino acids) sequence from Saccharomyces cerevisiae. The HSA mature gene was then inserted between EcoRI and NotI in the multiple cloning site of the pPIC9K recombinant expression vector;

[0072] The coding sequence AAAAGA for two dibasic amino acids (-Lys-Arg-) of lysine and arginine was inserted after the EcoRI restriction site at the 5' end of the target gene. The specific sequence is SEQ ID NO: 4. The double termination codon TAATAG was inserted before the NotI restriction site at the 3' end of the target gene. The specific sequence is SEQ ID NO: 5.

[0073] The recombinant expression vector constructed in step S200 is specifically

[0074] The optimized gene encoding human serum albumin synthesized by chemical synthesis was cut from the cloning vector using EcoRI-NotI double enzyme digestion, and the target gene fragment was recovered using a DNA recovery kit from the cut gel strip of corresponding size; the fragment containing the target gene was cloned into the recombinant expression vector digested with the corresponding double enzyme digestion to construct the recombinant expression vector.

[0075] The step S300 specifically comprises linearizing the recombinant expression vector obtained in step S200 using restriction endonuclease SacI or Bgl II, and transforming the linearized recombinant expression vector into a Pichia pastoris host bacterium using an electroporation method to obtain the novel host bacterium.

[0076] The nucleotide sequence of the recombinant expression vector is shown in SEQ ID NO: 1.

[0077] The recombinant expression vector is any one of pPIC9, pPIC3, pPICZαABC, pPIC3.5K, pHIL-S1, pHIL-D2, pA0804, pA0815, pGAPZαABC, pPIC6αABC, and pPIC9K.

[0078] The recombinant expression vector is HSA-pPIC9K.

[0079] The Pichia pastoris host strain is Pichia pastoris CBS7435

[0080] The relevant process and experimental data for constructing a novel host strain that highly expresses human serum albumin in this example are as follows:

[0081] The materials and equipment used include:

[0082] 1. Bacteria

[0083] 1. Pichia pastoris host strain GS115 (Pichia pastoris (his4) NRRL Y-15851);

[0084] 2. Pichia pastoris host strain CBS7435 (Pichia pastoris NRRL Y-11430);

[0085] 3. Escherichia coli host bacteria:

[0086] E.coli JM109 F'[(recA1,supE44endA1hsdR17gyrA96 relAl thi△(lac-proAB)

[0087] F'[traD36 proAB*lacI a lacZ△M15]);

[0088] E. coli HB101(supE44 hsd S20(rB-mB-)recA:ara-14proA2lac Y:galK2rpsL20xyl-5mtl-1).

[0089] The above E. coli host bacteria are used for cloning target genes and constructing and preparing plasmids.

[0090] 2. Main Reagents

[0091] 1. DNA restriction endonucleases, T4 DNA ligase, and polymerase were purchased from GIBCO-BRL, Pharmacia, Bio-Labs, and Huamei Bioengineering Co., Ltd., respectively.

[0092] 2. Casein hydrolysate (product of MERK, Germany);

[0093] 3. Bacto-yeast extract (product of Difco, USA);

[0094] 4. PCR amplification kit (product of Pharmacia, Sweden);

[0095] 5. DNA sequence analysis kit (USB company, USA);

[0096] 6. Acrylamide (Acr), N,N-dimethylbisacrylamide (Bis), sodium dodecyl sulfate (SDS), guanidine hydrochloride, urea, TEMED (products of Sigma, UK);

[0097] 7. IPTG, X-gal, DTT, Agarose (products of Sigma, UK);

[0098] 8. YNB, Biotin, Agar (products of Difco, USA);

[0099] 9. Sorbitol, glucose, L-histidine, L-lysine, L-methionine, L-leucine, L-isoleucine, L-glutamic acid (products of Sigma, USA);

[0100] 10. Glycerol, methanol (Shanghai Chemical Reagent Factory);

[0101] 11. Enzyme reaction solution:

[0102] Restriction enzyme high salt buffer: 10 mM Tris-HCl (pH 7.5), 100 mM NaCl, 10 mM MgCl2;

[0103] Restriction enzyme neutral salt buffer: 50mM Tris-HCl (pH 7.5), 50mM NaCl, 10mM MgCl2;

[0104] Restriction enzyme low-salt buffer: 10 mM Tris-HCl (pH 8.0), 10 mM MgCl2;

[0105] T4 DNA ligase buffer: 50 mM Tris-HCl (pH 8.0), 10 mM MgCl2, 10 mM DTT, 1 mM ATP;

[0106] 13.SDS-PAGE protein electrophoresis reagent:

[0107] Running buffer: 192 mM glycine, 25 mM Tris-HCl, 0.1% SDS, pH 8.3;

[0108] Stacking gel buffer: 125 mM Tris-HCl, 0.1% SDS, pH 6.8;

[0109] Separation gel buffer: 375 mM Tris-HCl, 0.1% SDS, pH 8.8;

[0110] Sample buffer (1×): 50 mM Tris-HCl (p6.8), 1% SDS, 10% glycerol, 2.5% mercaptoethanol, 0.05% bromophenol blue;

[0111] 30% acrylic acid amide: 29% acrylic acid amide, 1% N, N-dimethylbisacrylamide;

[0112] Coomassie Brilliant Blue staining solution: 0.25% (W / V) Coomassie Brilliant Blue G-250, 5% Hac;

[0113] 45% ethanol decolorizing solution: 7.5% HAc, 10% ethanol;

[0114] 13. Commonly used buffers:

[0115] TE buffer: 10 mM Tris-HCl (pH 8.0), 1 mM EDTA;

[0116] STE buffer: 10 mM Tris-HCl (pH 8.0), 1 mM EDTA, 20 mM NaCl PBS buffer: 10 mM NaH, POq-Na, HPO3 (pH 7.0), 150 mM NaCl;

[0117] 10X TBS buffer: 108 g Tris base, 55 g boric acid, 40 ml 0.5 M EDTA per liter, pH 8.0;

[0118] 50X TAE buffer: 242 g Tris base, 57.1 ml glacial acetic acid, 100 ml EDTA (0.5 M) per liter, pH 8.0;

[0119] Saturated phenol: redistilled and saturated with TE buffer, aliquoted and stored at 20°C;

[0120] Phenol:chloroform:isoamyl alcohol (V / V):1:1:0.8;

[0121] Chloroform:isoamyl alcohol (V / V): 24:1.

[0122] 3. Main instruments and equipment

[0123] 1. ABI381A automatic DNA synthesizer, a product of Applied Biosystems (ABI), USA;

[0124] 2.5L RIBE-5 fully automatic fermenter, a product of Shanghai Guoqiang Biochemical Engineering Equipment Co., Ltd.

[0125] 3.15L Biocenter 15F fully automatic fermenter, a product of Shanghai Guoqiang Biochemical Engineering Equipment Co., Ltd. (software system: Fermentation Star);

[0126] 4.50-liter Biocenter 50F fully automatic fermenter, a product of Shanghai Guoqiang Biochemical Engineering Equipment Co., Ltd. (software system: Fermentation Star);

[0127] 5. 100-liter Biocenter 100F fully automatic fermenter, a product of Shanghai Guoqiang Biochemical Engineering Equipment Co., Ltd. (software system: Fermentation Star);

[0128] 6.500 liters fully automatic Bplus bioreactor, a product of B. Braun, Germany;

[0129] 7.SDL-100 protein purification system, Suzhou Saipu Instrument Co., Ltd. (medium-pressure chromatography workstation, software SCG);

[0130] 8. Agilent High Performance Liquid Spectrometer, Agilent Technologies, 1260infinity, a product of Agilent, USA;

[0131] 9. External pressure ultrafiltration membrane assembly (filtration accuracy: 30KD), product of Huzhou Keliu Membrane Technology Co., Ltd.

[0132] 10. External pressure ultrafiltration membrane assembly (filtration accuracy: 100KD), product of Huzhou Keliu Membrane Technology Co., Ltd.

[0133] 11. Full wavelength microplate reader, Thermo Fisher 1510, a product of Thermo Fisher Scientific, USA;

[0134] 12. Electroporation instrument, Micropulser411BR10654, BIO-RAD, USA.

[0135] IV. Experimental Methods

[0136] (1) Culture medium and culture conditions

[0137] Escherichia coli culture medium LB (1% bacto-typtone, 0.5% bacto-yeast extract, 1% NaCl), solid medium with 15 g / L Agar powder, E. coli cultured at 37°C; Pichia pastoris rich medium YPD (1% Yeast extract, 2% peptone, 2% dextrose); Pichia pastoris protoplast regeneration medium RBD [1M sorbital, 1% dextrose, 1.34% YNB, 4 × 10 5Biotin, 0.005% amino acid mixture (including L-glutamic acid, L-methionine, L-leucine, L-isoleucine, and L-lysine)]. For solid culture, add 2% agar powder to the liquid culture. Pichia pastoris shake flask media BMGY and BMMY (1% yeast extract, 2% peptone, 100 mM PBS buffer, pH 6.0, 1.34% YNB, 4 x 105% biotin, 1% glycerol or 0.5% methanol) were cultured at 30°C.

[0138] (2) Pichia pastoris fermentation tank high-density fermentation medium and culture conditions 1:

[0139] A. 10×Basal Salts:

[0140] 1. H3PO4, 85% 42ml

[0141] 2.CaSO2·2H2 O 1.8g / L

[0142] 3.K2SO4 28.6g / L

[0143] 4.MgSO4·7H2 O 23.4g / L

[0144] 5.KOH 6.5g / L

[0145] B.250×PTMl salts:

[0146] 1.CuSO4·5H2 O 6g / L

[0147] 2.KI 0.08g / L

[0148] 3.MnSO4·H2O 3g / L

[0149] 4.Na2MoO4·2H2 O 0.2g / L

[0150] 5.H3BO3 0.02g / L

[0151] 6. CoCl2 0.5g / L

[0152] 7. ZnCl2 20g / L

[0153] 8.FeSO4·7H2O 65g / L

[0154] 9. Biotin 0.2g / L

[0155] 10.H2SO4 5ml

[0156] C.glycerol 8% (V / V)

[0157] D.Feed medium 50%glycerol(1L)+12ml / L PTM1

[0158] E.Induced medium 100% methanol(1L)+12ml / L PTM1

[0159] F.Dissolved O2(DO) >20%

[0160] G. pH 5.0-5.8

[0161] H.Temperature 20-30℃

[0162] (III) Pichia pastoris fermentation tank high-density fermentation medium and culture conditions 2: Preparation of solution A:

[0163] YPD medium (50 ml):

[0164] 1. Yeast extract 0.5g

[0165] 2. Peptone 1g

[0166] 3. Glucose 1g

[0167] The above YPD medium was used to culture the first-level seed bacteria of Pichia pastoris.

[0168] Preparation of Solution B:

[0169] BSM medium (1L):

[0170] 1. 98% glycerol 63g / L

[0171] 2. ddH2O (ultrapure water) 912ml

[0172] 3. CaSO2·2H2O 0.46g / L

[0173] 4. MgSO4·7H2 O 5.84g / L

[0174] 5. K2SO4 7.34g / L

[0175] 6. (NH4)2SO4 9g / L

[0176] The BSM medium was used for the cultivation of secondary seed bacteria of Pichia pastoris and as the main nutrient medium for yeast cultivation in a bioreactor.

[0177] Preparation of Solution C:

[0178] Preparation of sodium hexametaphosphate (HMP) solution (150ml):

[0179] 1. (NaPO3)6(Sodium hexametaphosphate) 30g

[0180] 2. ddH2O (ultrapure water) 150ml

[0181] Preparation of Solution D:

[0182] PTM1 solution (1 L):

[0183] 1.CuSO4·5H2 O 6g / L

[0184] 2.KI 0.08g / L

[0185] 3.MnSO4·H2O 3g / L

[0186] 4.Na2MoO4·2H2 O 0.2g / L

[0187] 5.H3BO3 0.02g / L

[0188] 6. CoCl2 0.5g / L

[0189] 7. ZnCl2 20g / L

[0190] 8.FeSO4·7H2O 65g / L

[0191] 9. Biotin 0.2g / L

[0192] 10.H2SO4 5ml

[0193] (IV) Plasmid extraction

[0194] 1. Small-scale plasmid extraction

[0195] Pick a single clone of bacteria and inoculate it into 2 ml of LB medium containing the corresponding antibiotics, and shake it at 37°C overnight. The next day, take 1.5 ml of the bacterial solution into an Eppendorf tube, centrifuge and precipitate the bacteria, and remove the supernatant. Place the bacterial pellet in an ice bath, add 100 μl of solution I (50 mM Glucose, 25 mM Tris-HCl, 10 mM EDTA, pH 8.0) in sequence, shake and mix, and incubate at room temperature for 5 minutes; add 200 μl of solution II (0.2 N NaOH, 1% SDS), turn and mix, and ice bath for 5 minutes; add 150 μl of solution III (3 M NaAc, pH 4.8), shake and mix gently, and ice bath for 5 minutes; add 450 μl of redistilled phenol / chloroform (1:1), mix and centrifuge at 12,000 rpm for 10 minutes, carefully aspirate the upper aqueous phase into 2 volumes of pre-cooled anhydrous ethanol, place in a -20°C refrigerator for 2 hours, and centrifuge at 12,000 rpm. After 15 minutes, aspirate the ethanol, carefully add 500μl 70% ethanol to wash and remove salt, centrifuge and drain, add 18μl TE and 2μl RNAase enzyme solution, and keep at 37℃ for 1 hour for enzyme digestion identification and further cloning.

[0196] 2. Large-scale plasmid extraction

[0197] Take 500 ml of overnight culture solution, centrifuge at 5000 rpm for 10 min at 4°C, add 100 ml of STE, resuspend and wash the cells, and then centrifuge to collect the cells. Then add solution I (50 mM Glucose, 25 mM Tris-HCl, 10 mM EDTA, pH

[0198] 8.0) 18 ml, lysozyme (10 mg / ml, 1% SDS) 2 ml, incubate at room temperature for 10 min; add solution II (0.2 N NaOH, 1% SDS) 40 ml, mix gently (until the bacterial solution is transparent), ice bath for 5 min; then add solution III (3 M NaAc, pH

[0199] Prepare 20 ml of 4.8) solution, mix well, and place on ice for 10 min; extract twice with an equal volume of phenol:chloroform (1:1) solution, add 2 volumes of pre-cooled anhydrous ethanol and let it stand at -20°C overnight, centrifuge at 12,000 rpm for 15 min, discard the supernatant, wash the precipitate 1-2 times with 70% ethanol, drain and dissolve in 3 ml of TE, add 10 μl of RNase solution (10 mg / ml), incubate at 37°C for 30 min, apply to a Sepharose 2B column (1×10 cm, equilibrated with TE), and use TE (pH 7.6) as the eluent to collect the first peak (high molecular weight DNA). After the collected sample is quantified, add 2 volumes of pre-cooled anhydrous ethanol and 1 / 10 volume of 3M NaAc (pH 5.2), mix well, and place in a -20°C refrigerator overnight. Centrifuge at 12,000 rpm for 15 minutes, discard the supernatant, and wash the precipitate 1-2 times with 70% ethanol. After draining, dissolve it in 1 ml of TE and measure the DNA content using an ultraviolet spectrophotometer at 260 nm. The large-scale extracted recombinant plasmid DNA can be used for the protoplast transformation of the Pichia pastoris host strain of the present invention and for long-term cryopreservation.

[0200] (V) Preparation of E. coli competent cells and transformation of recombinant plasmids

[0201] Inoculate 2 ml of LB broth with E. coli host cells and shake overnight at 37°C. The next day, inoculate 500 ml of overnight culture into 50 ml of LB broth and shake at 37°C at 300 rpm for 1 hour, until the cell density reaches 0.5 OD600. Centrifuge at 5000 rpm at 4°C for 5 minutes. Decant the supernatant and resuspend the cells in 25 ml of cold solution containing 100 mM CaCl2 and 10 mM Tris-HCl (pH 7.4). Place on ice for 30-60 minutes. Centrifuge again at 5000 rpm at 4°C for 5 minutes. Carefully decant the supernatant and resuspend the cells in 2 ml of cold calcium chloride solution. Place on ice for 40 minutes before use for transformation.

[0202] Suspend 200 μl of the freshly prepared competent E. coli cells in an Eppendorf tube, add 10 μl of the recombinant plasmid DNA ligase, incubate on ice for 30 min, and heat shock at 42°C for 2 min. Add 500 μl of LB culture medium and shake slowly on a shaker at 37°C for 1 hour. Centrifuge at 10,000 rpm for 10 sec. Pour off most of the LB, retaining approximately 200 μl of LB. Gently mix the bacterial suspension with a pipette tip, then divide the suspension into 50 μl and 150 μl portions. Apply each portion to an LB agarose plate containing 50 μg / ml ampicillin and incubate in a 37°C incubator for 8-16 hours.

[0203] The method for efficiently obtaining high-purity recombinant human serum albumin in this embodiment comprises the following steps:

[0204] S1. Prepare a novel host bacterium, which is deposited in the General Microbiology Center of China Culture Collection of Microorganisms with a deposit number of CGMCC No. 30175 and a deposit date of March 28, 2024;

[0205] S2, fermentation;

[0206] S3. Purification.

[0207] The novel host bacteria is an engineered bacterium expressing recombinant HSA obtained by introducing a recombinant expression vector into the Pichia pastoris CBS7435 strain. The nucleotide sequence of the recombinant expression vector is shown in SEQ ID NO: 1.

[0208] The fermentation in step S2 specifically includes

[0209] S210, preparing culture medium;

[0210] S220, electrode calibration;

[0211] S230, feeding;

[0212] S240, inoculating, inoculating a novel host bacterium that highly expresses human serum albumin;

[0213] S250, fermentation;

[0214] S260, place the can.

[0215] The recombinant expression vector comprises:

[0216] (1) A 5' regulatory region derived from Pichia pastoris, containing a promoter element, wherein the 5' regulatory region is selected from the alcohol oxidase AOX1 gene, the dihydroxyacetone synthase DAS1 gene, or the histidinol dehydrogenase HIS4 gene derived from Pichia pastoris, and the 3' end of the regulatory region is connected to the sequence of (2) below;

[0217] (2) An optimized gene encoding human serum albumin, wherein the nucleotide sequence contained therein is as shown in SEQ ID NO: 2, and the amino acid sequence contained therein is as shown in SEQ ID NO: 3;

[0218] (3) A 3' terminator sequence derived from methanol yeast, wherein the 3' terminator sequence is selected from the 3' terminator sequence of the AOX1 gene, AOX2 gene or His4 gene derived from Pichia pastoris.

[0219] For the optimized gene encoding human serum albumin, its nucleic acid sequence is 1755bp in length, and the corresponding encoded amino acid sequence is 585 amino acids. It is one of the longest functional genes chemically synthesized internationally to date.

[0220] The present invention involves a novel and specific optimization design of the HSA gene. The design utilized three core molecular biology databases: 1. International Nucleotide Sequence Databases (GenBank / EMBL / DDBJ); 2. Swiss Protein Sequence and Annotation Database (Swiss-PROT); and 3. Protein and Biomolecule Three-Dimensional Structure Database (Protein Data Bank, PDB) provided by Brookhaven National Laboratory in the United States. Multiple computer software packages (including the GENESIS and PROSIS software packages developed by the Genetic Computer Group at the University of Wisconsin, the Caltec software package developed by the California Institute of Technology, the DNASIS and PROSIS software packages provided by Pharmacia, Sweden, and other programs) were then used for comprehensive auxiliary analysis, ultimately resulting in the optimized gene encoding human serum albumin.

[0221] Among them, also include

[0222] At least one marker gene that can be selected in Escherichia coli;

[0223] A DNA segment with a replication origin capable of replicating in an Escherichia coli host bacterium;

[0224] The invention also comprises at least two marker genes that can be selected in yeast.

[0225] In the optimized gene encoding human serum albumin, the preferred codons of the Pichia pastoris alcohol oxidase (AOX1) gene are selected and the preferred codons of the gene are controlled to account for 90% of the total number of codons encoded in the optimized gene.

[0226] In the optimized gene encoding human serum albumin, three restriction endonuclease sites, SalI, HindIII, and XbaI, are sequentially inserted from 5' to 3' inside the optimized gene, so that the optimized gene is relatively evenly divided into four large fragments, which is convenient for splicing, cloning and assembly of synthetic genes.

[0227] In the optimized gene encoding human serum albumin, continuous GC pairing is reduced and AT pairing preferred by Pichia pastoris is increased, so that the GC content within the optimized gene is adjusted to 45-50%. In this embodiment, the optimal ratio is preferably 47.64%, which is conducive to the high expression of the target gene (see Figure 1 ).

[0228] The optimized gene encoding human serum albumin also includes an expression reading frame of

[0229] The 5' restriction endonuclease BamHI site was inserted into the 5' regulatory region (promoter region) of the AOX1 gene, followed by 10 deoxyoligonucleotides CCAAACGATG (containing the Kozak sequence of eukaryotic genes, i.e., AXXATG), and then the yeast α-mating child leader peptide (85 amino acids) sequence from Saccharomyces cerevisiae. The HSA mature gene was then inserted between EcoRI and NotI in the multiple cloning site of the pPIC9K recombinant expression vector;

[0230] The coding sequence AAAAGA for two double basic amino acids (-Lys-Arg-) of lysine and arginine was inserted after the EcoRI restriction site at the 5' end of the target gene. The specific sequence is SEQ ID NO: 4. The double termination codon TAATAG was inserted before the NotI restriction site at the 3' end of the target gene. The specific sequence is SEQ ID NO: 5. Figure 2 ; The coding sequence AAAAGA for two double basic amino acids (-Lys-Arg-) of lysine and arginine was inserted after the EcoRI restriction site at the 5' end of the target gene for processing and cleavage by the yeast endogenous KEX-2 protease; the double termination codon TAATAG was inserted before the NotI restriction site at the 3' end of the target gene to strengthen the termination signal of translation and prevent read-through during gene expression.

[0231] The mature gene encoding human serum albumin (1755 bp) was cut out from the pUC18 cloning vector by EcoRI-SmaI double enzyme digestion, and the fragment was identified by 1% agarose gel electrophoresis. Figure 3 (A: Lane 1 represents the recombinant plasmid; Lane 2 represents the recombinant plasmid digested with EcoRI and SmaI; Lane M represents the molecular weight standard KB Ladder. B: The two lanes represent the molecular weight standard KB Ladder and DL3000, respectively), which is consistent with the expected results; the KpnI of the multiple cloning site of the pUC18 cloning vector was changed to NotI; the chemically synthesized mature gene encoding human serum albumin (1755bp) was cut out from the pUC18 cloning vector using EcoRI-NotI double enzyme digestion, and the corresponding size gel strip was cut out and the target gene fragment was recovered using a DNA recovery kit. The HSA fragment cut out from the pUC18 cloning vector using EcoRI-NotI double enzyme digestion was cloned into the Pichia pastoris recombinant expression vector pPIC9K digested with the corresponding double enzymes to construct the recombinant expression vector HSA-pPIC9K (containing the HSAEcoRI-NotI fragment). The specific recombinant vector flow chart is shown in the figure. Figure 4, the ligation reaction system is:

[0232]

[0233] Ligation was performed overnight at 16°C in a 20 μl reaction system.

[0234] The ligation solution containing the recombinant plasmid HSA-pPIC9K was added to two concentrations, 4 μl and 8 μl, respectively, to transform competent E. coli JM109 host cells. The cells were spread onto LB plates (containing 20 μg / ml ampicillin) and cultured overnight at 37°C. Subsequently, 18 colonies containing the recombinant plasmid HSA-pPIC9K were randomly selected and inoculated into 2 ml of LB (containing 20 μg / ml ampicillin). The plates were shaken on a shaker for 6-8 hours. The double-stranded DNA of the plasmid was rapidly extracted using alkaline denaturation. The plasmids were then digested with EcoRI-NotI and subjected to electrophoresis on a 1% agarose gel to identify recombinants containing the HSA gene of the appropriate size. Five clones containing the HSA EcoRI-NotI fragment were identified. A large amount of HSA-pPIC9K recombinant plasmid was extracted from the inoculum of the E. coli host bacteria containing the HSA-pPIC9K recombinant plasmid identified above by the large-scale plasmid extraction method for long-term storage or subsequent transformation into the Pichia pastoris host bacteria. The specific design details and sequencing results of the HSA-pPIC9K recombinant plasmid were constructed as shown in Figure 4 and Figure 5 、 6 、7.

[0235] The recombinant plasmid is linearized using restriction enzyme SacI or Bgl II. The linearized recombinant plasmid is transformed into the Pichia pastoris host bacteria, i.e., the transformed host bacteria GS115 or CBS7435, by electroporation. The specific implementation method is as follows:

[0236] a. Culture medium preparation

[0237] 1. BMGY medium: Dissolve 10 g yeast powder and 20 g peptone in 700 mL deionized water. Sterilize by moist heat for 20 min. After cooling, add 100 mL 1 M potassium phosphate buffer, pH 6.0, 100 mL 10× YNB, 2 mL 500× B, and 100 mL 10× GY. Store at 4°C.

[0238] 2. BMMY medium: Dissolve 10 g yeast powder and 20 g peptone in 700 mL deionized water, sterilize with moist heat for 30 min, cool, add 100 mL 1 M potassium phosphate buffer (pH 6.0), 100 mL 10× YNB, 2 mL 500× B, and 100 mL 10× M, and store at 4°C.

[0239] 3.MD medium: Add 100 mL of 10×YNB, 2 mL of 500×B, and 100 mL of 10×D to 800 mL of sterile water and store at 4°C.

[0240] 4.1M potassium phosphate buffer, pH 6.0: 132mL 1M K2HPO4, 868mL 1M KH2PO4, pH 6.0, sterilize by moist heat, store at 4℃.

[0241] 5.10× YNB: Dissolve 134 g of YNB (containing ammonium sulfate) in 1000 mL of deionized water, filter sterilize, and store at 4°C.

[0242] 6.500×B: Dissolve 20 mg of Biotin in 100 mL of deionized water, filter sterilize, and store at 4°C.

[0243] 7.10×M: Mix 5 mL of methanol with 95 mL of deionized water, filter sterilize, and store at 4°C.

[0244] 8.10×GY: Mix 100 mL of glycerol with 900 mL of deionized water, sterilize by moist heat, and store at 4°C.

[0245] 9.10×D: Dissolve 100 g glucose in 1000 mL deionized water, filter sterilize, and store at 4°C.

[0246] 10.1M sorbitol: Dissolve 18.2g D-sorbitol in 100mL deionized water, filter sterilize, and store at 4°C. b. Bacteria preparation

[0247] 1. Pick a single colony of Pichia pastoris (GS115 or CBS7435) and inoculate it into a 50 ml Erlenmeyer flask containing 5 ml YPD medium. Incubate overnight at 30°C and 250-300 rpm.

[0248] 2. Take 100-500 μl of culture and inoculate into 2 L triangular shake flask containing 500 ml of fresh culture medium. Cultivate overnight at 28-30°C and 250-300 rpm until OD600 reaches 1.3-1.5.

[0249] 3. Centrifuge the cell culture at 1500g for 5 min at 4°C and resuspend the pellet in 500 ml of ice-cold sterile water.

[0250] 4. Centrifuge as in step 3 and resuspend the bacterial pellet in 250 ml of ice-cold sterile water;

[0251] 5. Centrifuge as in step 3 and resuspend the bacterial pellet in 20 ml of ice-cold 1 M sorbitol solution;

[0252] 6. Centrifuge as in step 3 and resuspend the pellet in 1 ml of ice-cold 1 M sorbitol solution to a final volume of approximately 1.5 ml.

[0253] Note: It can be packaged into 80μl packages and frozen, but its transformation efficiency will be affected (within 2 weeks).

[0254] c. Electroporation

[0255] 1. Add 80 μL of treated Pichia competent cells and 5-20 μg of linearized DNA (dissolved in double-distilled water, volume 5-10 μL) to a 1.5 mL pre-chilled centrifuge tube and mix thoroughly. Then transfer the mixture into a 0.2 cm transformation cuvette that has been pre-chilled.

[0256] 2. Ice-bathe the transformation cup containing the transformation mixture for 5 minutes;

[0257] 3. According to the information provided by the electroporation instrument, refer to other literature and explore many times to determine the appropriate voltage, current, capacitance and other parameters, and perform electroporation according to the optimized parameters; the relevant parameters recommended by the present invention are: voltage 1500-1800V; capacitance 25μF; resistance 200-400Ω, and electroporation time 4-10msec.

[0258] 4. Immediately after the pulse, add 1 mL of ice-cold 1 M sorbitol solution to the transformation cup, and then transfer the transformation solution to a new 1.5 mL centrifuge tube;

[0259] 5. Incubate on a shaker at 28°C for 1-2 hours;

[0260] 6. Pipette 50-200 μL of the transformation solution of Pichia pastoris host strain GS115 or CBS7435 and coat it on MD plates;

[0261] 7. Culture in a 28°C incubator for about 3-4 days until many monoclonal positive colonies containing the recombinant plasmid (yeast transformants) appear.

[0262] d. Screening of multi-copy transformants

[0263] 1. Rinse the MD plate with yeast transformants thoroughly with 2 mL of sterile water, then pipette the bacterial solution and temporarily store it in a centrifuge tube;

[0264] 2. The resulting bacterial solution was spread onto YPD plates containing G418 resistance, with 100 μL of the bacterial solution applied to each plate. The G418 antibiotic content was configured into different concentration gradients: 0.25%, 0.5%, 1.0%, 1.25%, 1.5%, 1.75%, 2.0%, etc.

[0265] 3. Place the plate coated with the bacterial solution in a 28°C incubator and culture for 4 to 12 days to grow white monoclonal colonies with different G418 resistance (i.e., obtain Pichia pastoris transformants with different copy numbers).

[0266] The experimental results of electroporation of host bacteria GS115 or CBS7435 in this example are as follows: Figure 8 、 Figure 9 、 Figure 10 , as shown in Table 1 and Table 2.

[0267] Table 1 Results of multi-copy screening experiments of Pichia pastoris GS115 engineered strains

[0268]

[0269]

[0270] Note: In Table 1, a G418 resistance of 0.25 means that the host bacteria contains 1 copy of the exogenous gene, and so on.

[0271] Table 2 Results of multi-copy screening experiment of Pichia pastoris CBS7435 engineered strain

[0272]

[0273] Note: In Table 2, a G418 resistance of 0.25 means that the host bacteria contains 1 copy of the exogenous gene, and so on.

[0274] Six clones containing different copy numbers of the recombinant plasmid HSA-pPIC9K, identified by electroporation, were randomly selected from YPD plates and inoculated into 4 ml tubes of BMGY liquid medium. The cells were shaken overnight at 28°C at 200-250 rpm. The cells were centrifuged at 1500-3000 g for 5 minutes at room temperature to collect the cells. The cells were then resuspended in 4 ml of the original culture volume of BMMY and shaken at 28°C at 250-300 rpm for 36-48 hours. The cells were then centrifuged at 5000 rpm for 10 minutes, and 30 μL of the supernatant was collected and vacuum-evacuated. The samples were then subjected to 10% SDS-PAGE electrophoresis, using pPIC9K empty vector expression as a control to identify high-expressing clones. These high-expressing clones were then cryopreserved in 15% glycerol and used as engineered strains for further expression experiments.

[0275] For the above-mentioned engineered high-expression strain, a small-scale induction experiment was performed. If it was Pichia pastoris GS115 strain, the experimental protocol would be as follows: glycerol bacteria → YPD → BMGY → BMGY → BMMY: after the glycerol bacteria were inoculated in YPD liquid medium for rejuvenation, 1 ml of the seed culture was transferred to 50 ml of BMGY culture medium and shaken at 28°C, 200-250 rpm for 18-24 hours; then 40 ml of the seed culture was inoculated into 1000 ml of BMGY culture medium at a 4% inoculum volume and shaken on a shaker for 24-30 hours at 28°C, 250-300 rpm; the culture was centrifuged at 5000 rpm for 5 min, the supernatant was discarded, and the cells were then suspended in 500 ml of BMMY induction expression medium, placed at 28°C, 250-300 rpm, and continued to shake on a shaker for 3-4 days, with additional methanol added every 24 hours (100% methanol was added to a final concentration of 0.5%). At this time, the cell density of Pichia pastoris engineering bacteria has generally reached 18-20 OD 600 Most of the exogenous protein expressed by the gene is secreted into the liquid culture medium. The fermentation medium is centrifuged at 10,000 rpm for 20 minutes at 4°C. The cells are discarded, and the supernatant, which contains a large amount of HSA expression product, is analyzed by SDS-PAGE electrophoresis. This small-scale induction experiment is used to analyze and identify the expression level of recombinant HSA.

[0276] For the above-mentioned engineered high-expression strain, a small-scale induction experiment was conducted. If it was the Pichia pastoris CBS7435 strain, the experimental protocol would follow the steps of glycerol culture → YPD → YPD → BSM → BSM: the sample loading amount was similar to that of the GS115 strain.

[0277] In this example, some results of the small-scale induction experiment of some Pichia pastoris GS115 or CBS7435 strains are shown in Figure 11 、 12 and Figure 13 、 14 .

[0278] The engineered strains that showed clear expression bands in the pilot induction experiments were further cultured and fermented at high cell densities using fed-batch fermentation in 5L, 30L, 50L, and 500L fermentors. This was done to explore the Pichia pastoris BSM fermentation process and further validate the pilot fermentation process for the electroporated GS115 or CBS7435 engineered strains. The specific implementation plan is as follows:

[0279] S210, preparing culture medium;

[0280] The fermentation base medium of this embodiment is prepared as shown in Table 3 below.

[0281] Table 3 Fermentation base medium preparation (prepared by 6L volume)

[0282] Reagents Formula (g / L) Preparation volume 6L <![CDATA[H3PO4]]> 26.7ml 160ml <![CDATA[CaSO4·2H2O]]> 0.47 2.8 <![CDATA[K2SO4]]> 9.1 55 <![CDATA[MgSO4·7H2O]]> 7.5 45 KOH 4.13 25 98% glycerol 40 240 defoaming agent 0.5ml 3ml

[0283] When preparing the fermentation substrate, store the phosphoric acid and glycerol separately in a measuring cup or beaker. Dissolve the other inorganic salts in approximately 2L of purified water, adding each reagent after the previous one has completely dissolved. Finally, dissolve the KOH separately and avoid mixing it with the inorganic salts.

[0284] S220, electrode calibration, electrode calibration includes pH electrode calibration and dissolved oxygen electrode calibration.

[0285] pH electrode calibration: First, prepare standard pH electrode solutions of pH 6.86 and 4.00, a wash bottle, and a paper towel. Connect the pH electrode to the fermentation tank electrode line. Rinse the electrode with the wash bottle, absorb water with a paper towel, and insert the pH 6.86 electrode solution. After the pH value displayed on the fermentation tank stabilizes, press the calibration button to calibrate the zero point. Remove the electrode, rinse it with the wash bottle, absorb water with a paper towel, and insert the pH 4.00 electrode solution. After the pH value displayed stabilizes, press the calibration button to calibrate the slope. Repeat this process three times. The pH display should be consistent with the pH value in the electrode solution, indicating that the pH electrode calibration is complete.

[0286] Dissolved oxygen electrode calibration: Connect the dissolved oxygen electrode to the fermentation tank electrode line, clean it, and then insert it into a saturated anhydrous sodium sulfite solution. After standing for 15 minutes, the dissolved oxygen display value should no longer change. At this time, press the calibration key to calibrate the dissolved oxygen zero point. The slope of the dissolved oxygen electrode should be calibrated to 100% with stirring at 100 rpm, ventilation at 0.5 vvm, and a tank pressure of 0.05 MPa before fermentation inoculation.

[0287] S230, feeding.

[0288] Feeding process: Add phosphoric acid and glycerol to the fermenter in sequence, followed by the inorganic salt solution, and finally KOH. Add purified water to a volume of 5 L (for reference, the tank weighs approximately 5 kg; after sterilization, the volume should be approximately 6 L). After adding the ingredients, the pH should be below 2. Prepare a total of 1 L of PTM1. Store sealed and protected from light.

[0289] 100% analytical grade methanol 3 L;

[0290] 50% glycerol feed 800ml:

[0291] Weigh 400 g of 98% glycerol, add purified water to 800 ml, dissolve and pour into a 1 L feeding bottle, autoclave at 121 ° C for 30 minutes, and cool for use.

[0292] S240, inoculating, inoculating a novel host bacterium that highly expresses human serum albumin;

[0293] Fermentation experimental process of Pichia pastoris engineered strain

[0294] 1. Seed preparation:

[0295] Take the glycerol bacteria numbered CBS7435-C1-C50 or GS115-G1-G30, add 100μl to 20ml of bacterial liquid to 100ml YPD medium as the first-level seed liquid, and culture at 28℃ and 200rpm for 24 hours; transfer 5ml of bacterial liquid to YPD 480ml / 2L conical flask as the first-level seed liquid, and continue to culture at 28℃ and 200rpm for 24 hours. Transfer 5ml of the first-level seed bacteria liquid to BSM medium 480ml / 2L conical flask (2 bottles in total) as the second-level seed liquid, and continue to culture at 28℃ and 200rpm for 24 hours. The OD of this second-level seed bacteria liquid before inoculation is 0.04. 600 It should be between 20 and 40.

[0296] Inoculate the fermenter with the fungus:

[0297] Before inoculation, confirm that the fermentation tank temperature is 30°C, set the pH to 5.0, and automatically adjust the pH with ammonia water. Then, use the flame circle inoculation method to connect the seed liquid to the fermentation tank to complete the inoculation. For flame circle inoculation, surround the fermentation tank inoculation port with an alcohol cotton ball and ignite it. Close the air inlet valve and open the exhaust valve until the tank pressure is around 0.02MPa. Use a special tool to slightly open the inoculation port, exhaust a small amount of air until there is no sound of air flowing out, and then completely unscrew the inoculation port. Open the packaging rope of the seed bacteria bottle and PTM1 container, remove the sealing film above the flame circle, and then pour the seed bacteria and PTM1 into the tube. Do not mix the seed bacteria and PTM1 before inoculation.

[0298] Recombinant human serum albumin fermentation culture stage:

[0299] (1) Basic culture stage of engineering bacteria

[0300] At the beginning of the fermentation of the engineered bacteria, the SCADA process control software was started to record data, fermentation time and batch number, and the graph record was turned on; from the time the inoculated bacteria were placed in the fermenter, relevant fermentation data (such as time, temperature, stirring, pH, DO, air flow, and tank pressure) were recorded regularly every 4 hours; the control parameters were set as follows: pH was controlled at 5.5±0.1 with ammonia water, and the temperature was controlled at 28±1°C; DO value was controlled to be above 30, air flow was 2vvm, and tank pressure was controlled at 0.03-0.04Mpa; after DO rebound (DO rebound refers to the DO value rising by more than 10 under the condition that no operation of fermenter ventilation, stirring, or tank pressure was performed), the transition culture phase was entered; sampling was taken to detect OD during the rebound 600 It should be around 50.

[0301] (2) Transitional culture stage of engineered bacteria:

[0302] The purpose of the transition culture phase of engineered bacteria is to further increase the biomass of engineered bacteria. Fermentation data is recorded every hour. During the transition culture phase, 50% glycerol needs to be added: after DO rebounds, 50% glycerol is added immediately (add 12ml / L of PTM1 solution containing biotin, about 10ml); at the same time, the stirring is adjusted to the maximum speed specified by the fermenter, the air flow is adjusted to 2vvm, and the tank pressure is adjusted to 0.04~0.08Mpa; under this condition, the feeding rate is to control the DO value at 30±10. Perform DO-Spike at least once every hour to ensure that the DO-Spike response time is less than 60 seconds. The feeding cycle is about 4 to 5 hours; when adding glycerol, adjust the pH set value every hour on average so that the pH is the induced pH value required by the project after the glycerol feeding is completed (for this fermentation, the pH in the induction stage is the same as the pH in the culture stage, both are 5.7, so there is no need to adjust the pH); at the end of the transition culture phase, OD 600 At this point, the wet weight of the bacterial culture was measured and retained for 0 h. Each subsequent sample was taken for wet weight measurement instead of OD. The glycerol feed was stopped and the methanol induction phase began.

[0303] (3) Engineering bacteria induced expression stage:

[0304] After stopping the addition of glycerol and observing the rebound of dissolved oxygen (DO), prepare to add methanol (add 12 ml / L of PTM1 to methanol); add 4 g / L of methanol at one time (in this experiment, 24 g of methanol was added at one time, and 30 ml of methanol can be added through the feed gasket with a disposable syringe). After the added methanol is consumed (DO rebound), begin adding methanol via DO-Spike. Optimally, a DO-Spike response time of less than 60 seconds is recommended, maintaining a DO value between 10 and 30. Simultaneously, adjust the temperature to the project-specified temperature (24°C for this experiment). Maintain the pH at the project-specified pH of 5.7. During the induction phase, perform DO-Spikes every 12 hours, recording the response time and other fermentation data. Samples are collected every 12 hours to check the pH and wet weight of the engineered bacteria. Centrifuge the culture, remove 100 μl of the supernatant, add electrophoresis buffer, boil at 100°C for 5 minutes, and store at -20°C. Store the remaining supernatant at 2-8°C until testing or electrophoresis analysis is performed. Label the samples carefully. Maintain a methanol concentration of 0.2-0.9% throughout the induction phase of the Pichia pastoris culture.

[0305] (4) Place the can

[0306] In the fermentation experiment of the Pichia pastoris engineered strain, the induction expression time of this experiment was about 200 hours, followed by tank release, solid-liquid separation and subsequent treatment; and the supernatant was collected for subsequent purification.

[0307] The detection of the target protein in the fermentation test process of Pichia pastoris is as follows:

[0308] In this embodiment, the fermentation process of Pichia pastoris in a fermenter is controlled and recorded in real time, and in particular, the target protein in the fermentation broth in the fermenter is tracked and detected online at different time points during the induction expression phase: The present invention uses the BCA Protein Concentration Assay Kit (Enhanced BCA Protein Assay Kit) of Biyuntian Biotechnology Co., Ltd. as a detection tool, and the BCA Protein Concentration Assay Kit (Enhanced) is developed based on the BCA method, one of the two most commonly used protein concentration detection methods in the world, and achieves high stability, high sensitivity and high compatibility of the protein concentration determination results. In this experiment, bovine serum albumin was used as a standard, and a standard curve and a linear equation (see Figure 18 ), quantitatively analyze the expression level of secreted HSA in each batch of fermentation broth in the fermenter; the specific method is to sample the fermentation broth in the fermenter at different time points during the induction expression phase, centrifuge the fermentation samples (using 5000g×20min), discard the bacteria, and retain the supernatant; after the fermentation of this batch is completed, perform SDS-PAGE electrophoresis on the retained fermentation supernatant samples, and then stain them with Coomassie Brilliant Blue to observe the electrophoresis results, see Figure 15 、 Figure 16 and Figure 17 On the other hand, the retained fermentation supernatant samples were appropriately diluted and loaded into a 96-well plate with a colorimetric reagent. The samples were assayed according to the instructions of the BCA Protein Concentration Assay Kit (Enhanced). The expression levels of human serum albumin at different time points during the fermentation process were calculated, and some of the results are shown in Tables 4 and 5. In addition, the expression levels of recombinant HSA from nine batches of fermentation experiments are shown in Table 6.

[0309] Table 4 Target protein concentrations in the supernatant of the engineered strain C7 at different time points in the 50 L fermenter fermentation test

[0310]

[0311] Table 5 Target protein concentrations in the supernatant of the engineered strain C1 at different time points in the 50 L fermenter fermentation test

[0312]

[0313] Table 6 Experimental results of multi-batch production of recombinant human serum albumin using high-density fermentation technology

[0314]

[0315] In Table 6, C represents CBS7435 engineered bacteria; G represents GS115 engineered bacteria

[0316] Step S300 is specifically as follows:

[0317] S310, taking out the fermentation liquid;

[0318] S320, centrifugation of the fermentation broth;

[0319] S330, membrane filtration of the supernatant;

[0320] S340, heat treatment;

[0321] S350, secondary membrane filtration;

[0322] S360, column chromatography;

[0323] The step S310 specifically involves taking out the fermentation liquid from the fermentation tank after the fermentation in step S2 is completed.

[0324] The step S320 specifically involves centrifuging the fermentation liquid taken out from the step S310 at 9000 rpm and controlling the temperature to below 30°C.

[0325] The step S330 specifically involves filtering the fermentation supernatant obtained after centrifugation in step S320 through a hollow fiber membrane to obtain filtered fermentation supernatant.

[0326] The step S340 specifically includes adding sodium octanoate to the filtered fermentation supernatant obtained in step S330 to make a final concentration of sodium octanoate of 5 mmol / L, adjusting the pH value to 5.8-7.0, and heating at 68° C. for 30 minutes; rapidly cooling, and then adjusting the pH value to 4.5 with acetic acid to obtain a heat-treated fermentation supernatant.

[0327] The step S350 specifically involves filtering the heat-treated fermentation supernatant obtained in step S340 through a hollow fiber membrane to obtain the fermentation supernatant to be purified.

[0328] The step S360 specifically involves performing chromatography on the fermentation supernatant to be purified obtained in S350 to obtain purified recombinant human serum albumin.

[0329] The column chromatography selection

[0330] Three-step column chromatography including TH-MC composite mode SP cation exchange column chromatography, hydroxyapatite type II (HAPⅡ) chromatography and DEAE anion exchange column chromatography;

[0331] or

[0332] Three-step column chromatography including TH-MC composite mode SP cation exchange column chromatography, hydroxyapatite type II (HAPⅡ) column chromatography and TA-phenyl-HIC hydrophobic column chromatography.

[0333] The purified recombinant human serum albumin sample was subjected to gel electrophoresis, and the gel electrophoresis showed a single band, such as Figure 19 The purity of the recombinant human serum albumin sample was 99.03% as shown in the HPLC liquid phase test. Figure 20 .

[0334] A preliminary study of mass spectrometry molecular weight characterization was conducted on the purified recombinant human serum albumin sample (No. P7901-PH-E) and the rHSA national standard (purchased from the China Food and Drug Administration Inspection Institute). Comparative studies were conducted using mass spectrometry-SEC and RP elution conditions under non-reducing and reducing conditions. The results showed that under the above conditions, the total ion chromatogram (TIC) chromatogram showed a single peak, and the peak time and peak shape were highly consistent (see Figure 21 and Figure 22 Further experiments were conducted to determine the molecular weight using electrospray mass spectrometry. The results showed that the recombinant human serum albumin sample (No. P7901-PH-E) provided by us and the rHSA national standard had reduced molecular weight mass spectrometry results of 66477.0 and 66487.5 Da, respectively, which were highly consistent with the theoretical molecular weight of HSA of 66472 Da. Figure 23 .

[0335] The method for constructing a novel host bacterium that highly expresses human serum albumin in this embodiment has the following beneficial effects:

[0336] 1) Through the optimization design of the full sequence of the target gene at the molecular level, the target gene with the best expression in Pichia pastoris is obtained; 2) At the cellular level, by introducing the latest international Pichia pastoris expression system host strain CBS7435, it is used for the gene expression of human serum albumin; the G418 resistance gene is used to screen Pichia pastoris transformants containing high copy numbers of exogenous genes, which are used to construct Pichia pastoris engineered bacteria with high-level expression of recombinant human serum albumin; 3) At the engineering level, by exploring optimization schemes for fermentation culture technology and reactor process control, the expression level of the target protein is further improved; 4) In terms of purification technology, the serious defects in the existing recombinant human serum albumin purification process are analyzed and learned, and the latest purification media, purification technologies, purification methods, etc. at home and abroad are introduced. Only pretreatment such as solid-liquid separation of fermentation broth, heat treatment and ultrafiltration concentration are used, and the entire purification process is completed through three-step column chromatography. The purity of recombinant human serum albumin reaches more than 99%, and the recovery rate of the entire purification process reaches more than 60%.

[0337] The above-mentioned embodiments only express a certain implementation method of the present invention, and the description thereof is relatively specific and detailed, but it cannot be understood as limiting the patent scope of the present invention. It should be pointed out that for ordinary technicians in this field, several variations and improvements can be made without departing from the concept of the present invention, which all fall within the scope of protection of the present invention. Therefore, the scope of protection of the patent of the present invention shall be based on the attached claims.

[0338] The present invention relates to the sequence:

[0339] SEQ ID NO: 1

[0340]

[0341] SEQ ID NO:2

[0342]

[0343] SEQ ID NO:3

[0344] DAHKSEVAHRFKDLGEENFKALVLIAFAQYLQQCPFEDHVKLVNEVTEFAKTCVADESAENCDKSLHTLFGDKLCTVATLRETYGEMADCCAKQEPERNECFLQHKDDNPNLPRLVRPEVDVMCTAFHDNEETFLKKYLYEIARRH PYFYAPELLFFAKRYKAAFTECCQAADKAACLLPCLDELRDEGKASSAKQRLKCASLQKFGERAFKAWAVARLSQRFPKAEFAEVSKLVTDLTKVHTECCHGDLLECADDRADLAKYICENQDSISSKLKECCEKPLLEKSHCIAE VENDEMPADLPSLAADFVESKDVCKNYAEAKDVFLGMFLYEYARRPDYSVVLLLRLAKTYETTLEKCAAADPHECYAKVFDEFKPLVEEPQNLIKQNCELFEQLGEYKFQNALLVRYTKKVPQVSTPTLVEVSRNLGKVGSKCCKHPEAKRMPCAEDYLSVVLNQLCVLHEKTPVSDRVTKCCTESLVNRRPCFSALEVDETYVPKEFNAETFHADICTLSEKERQIKKQTALVELVKHKPKATKEQLKAVMDDFAAFVEKCCKADDKETCFAEEGKKLVAASQAALGL

[0345] SEQ ID NO:4

[0346] GAATTCAAAAGA

[0347] SEQ ID NO:5

[0348] TAATAGGCGGGCCGC

Claims

1. A method for constructing a novel host bacterium that highly expresses human serum albumin, characterized in that: The construction method comprises S100, design of optimized gene encoding human serum albumin; S200, constructing a recombinant expression vector; S300, transforming the recombinant expression vector obtained in step S200 into a Pichia pastoris host bacterium by electroporation to obtain the novel host bacterium.

2. The method for constructing a novel host bacterium that highly expresses human serum albumin according to claim 1, characterized in that: The nucleotide sequence contained in the optimized gene encoding human serum albumin in step S100 is shown as SEQ ID NO:2, and the amino acid sequence contained therein is shown as SEQ ID NO:

3.

3. The method for constructing a novel host bacterium that highly expresses human serum albumin according to claim 1, characterized in that: In the step S100, in the optimized gene encoding human serum albumin, the preferred codons of the Pichia pastoris alcohol oxidase (AOX1) gene are selected and the preferred codons of the gene are controlled to account for 90% of the total number of codons encoded in the optimized gene.

4. The method for constructing a novel host bacterium that highly expresses human serum albumin according to claim 1, characterized in that: In the step S100, three restriction endonuclease sites, namely SalI, HindIII and XbaI, are sequentially inserted into the optimized gene encoding human serum albumin from the 5' to the 3' direction, so that the optimized gene is relatively evenly divided into four large fragments.

5. The method for constructing a novel host bacterium that highly expresses human serum albumin according to claim 1, characterized in that: In the step S100, in the optimized gene encoding human serum albumin, continuous GC pairing is reduced, and AT pairing preferred by Pichia pastoris is increased, so that the GC content inside the optimized gene is adjusted to 45-50%.

6. The method for constructing a novel host bacterium that highly expresses human serum albumin according to claim 1, characterized in that: The optimized gene encoding human serum albumin in step S100 also includes an expression reading frame of inserting the restriction endonuclease BamHI site at the 5' end into the 5' regulatory region (promoter region) of the AOX1 gene, followed by 10 deoxy-oligonucleotides CCAAACGATG (containing the Kozak sequence of eukaryotic genes, i.e. AXXATG), followed by a yeast a-mating son leader peptide (consisting of 85 amino acids) sequence from Saccharomyces cerevisiae, and then inserting the HSA mature gene between EcoRI and NotI in the multiple cloning site of the pPIC9K recombinant expression vector; The coding sequence AAAAGA of two dibasic amino acids (-Lys-Arg-) of lysine and arginine was inserted after the EcoRI restriction site at the 5' end of the target gene, and the specific sequence is SEQ ID NO: 4; the double termination codon TAATAG was inserted before the NotI restriction site at the 3' end of the target gene, and the specific sequence is SEQ ID NO:

5.

7. A method for constructing a novel host bacterium that highly expresses human serum albumin according to any one of claims 1 to 6, characterized in that: The step S200 of constructing the recombinant expression vector specifically comprises: The optimized gene encoding human serum albumin synthesized by chemical synthesis is cut out from the cloning vector by double restriction enzyme digestion with EcoRI-NotI, and the cut gel strip of corresponding size is used to recover the fragment of the target gene by DNA recovery kit; the fragment containing the target gene is cloned into the recombinant expression vector cut with the corresponding double restriction enzyme to construct the recombinant expression vector.

8. The method for constructing a novel host bacterium that highly expresses human serum albumin according to claim 7, characterized in that: The step S300 specifically comprises linearizing the recombinant expression vector obtained in step S200 using restriction endonuclease SacI or BglII, and transforming the linearized recombinant expression vector into a Pichia pastoris host bacterium using an electroporation method to obtain the novel host bacterium.

9. The method for constructing a novel host bacterium that highly expresses human serum albumin according to claim 8, characterized in that: The nucleotide sequence of the recombinant expression vector is shown in SEQ ID NO:

1.

10. The method for constructing a novel host bacterium that highly expresses human serum albumin according to claim 7, characterized in that: The recombinant expression vector is any one of pPIC9, pPIC3, pPICZαABC, pPIC3.5K, pHIL-S1, pHIL-D2, pA0804, pA0815, pGAPZαABC, pPIC6αABC, and pPIC9K.

11. The method for constructing a novel host bacterium that highly expresses human serum albumin according to claim 10, characterized in that: The recombinant expression vector is HSA-pPIC9K.

12. The method for constructing a novel host bacterium that highly expresses human serum albumin according to claim 8, characterized in that: The Pichia yeast host strain is Pichia pastoris CBS7435.

13. The method for constructing a novel host bacterium that highly expresses human serum albumin according to claim 1, characterized in that: The novel host bacteria is Pichia pastoris HSA-C16, which is deposited in the General Microbiology Center of China National Microbiological Culture Collection Administration, with the deposit number CGMCC No. 30175 and the deposit date March 28, 2024.

Citation Information

Cited By

  • Recombinant batroxobin as well as preparation method and application thereof

    CN121271846A

  • Method for constructing new host bacterium with high expression of human serum albumin

    WO2026037279A1